Viking Therapeutics
VKTX
143 hedge funds and large institutions have $212M invested in Viking Therapeutics in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 50 reducing their positions, and 17 closing their positions.
67% more call options, than puts
Call options by funds: $4.78M | Put options by funds: $2.87M
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
2% more funds holding
Funds holding: 140 → 143 (+3)
2.64% less ownership
Funds ownership: 54.37% → 51.73% (-2.6%)
8% less capital invested
Capital invested by funds: $230M → $212M (-$17.6M)
12% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.67M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$3.14M |
| 3 |
Two Sigma Advisers
New York
|
+$2.31M |
| 4 |
Two Sigma Investments
New York
|
+$1.37M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.69M |
| 2 |
Goldman Sachs
New York
|
-$3.31M |
| 3 |
DM
Deerfield Management
New York
|
-$2.03M |
| 4 |
Morgan Stanley
New York
|
-$1.55M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.52M |
VKTX Hedge Fund Activity: Q4 2020 in Review
143 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2020, worth a combined $212M — down 7.7% from $230M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VKTX positions and 17 closed out — a net gain of 3 holders — while 44 added to existing stakes and 50 trimmed.
The largest buyer was BlackRock, adding an estimated $3.67M. The largest seller was Fidelity Investments, cutting an estimated $9.69M.
- 143 institutional investors held Viking Therapeutics (VKTX) as of Q4 2020, up from 140 in Q3 2020.
- Funds reported $212M of Viking Therapeutics stock for Q4 2020, down 7.7% quarter-over-quarter.
- 20 funds opened new Viking Therapeutics positions in Q4 2020 and 17 closed out, a net change of +3 holders.
- The largest Viking Therapeutics buyer in Q4 2020 was BlackRock, an estimated $3.67M added.
- The largest Viking Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $9.69M sold.
Based on aggregated 13F filings for Q4 2020.